330 related articles for article (PubMed ID: 9798342)
1. Changes in immunological parameters after combination adjuvant therapy with intravenous DTIC, ACNU, and VCR, and local injection of IFN-beta (DAV + IFN-beta therapy) into malignant melanoma.
Umeda T; Aoki K; Yokoyama A; Ohara H; Hayashi O; Tanaka K; Nishioka K
J Dermatol; 1998 Sep; 25(9):569-72. PubMed ID: 9798342
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic implications of the kinetics of immunomodulation during single or combined treatment of melanoma patients with dacarbazine and interferon-alpha.
Konjević G; Jović V; Radulović S; Jelić S; Dzodić R; Spuzić I
Neoplasma; 2001; 48(3):175-81. PubMed ID: 11583285
[TBL] [Abstract][Full Text] [Related]
3. Local injection of interferon beta in malignant melanoma of the esophagus as adjuvant of systemic pre- and postoperative DAV chemotherapy: case report with 7 years of long-term survival.
Kawada K; Kawano T; Nagai K; Nishikage T; Nakajima Y; Tokairin Y; Ogiya K; Tanaka K; Iwai T
Gastrointest Endosc; 2007 Aug; 66(2):408-10. PubMed ID: 17643724
[No Abstract] [Full Text] [Related]
4. The use of DAV (DTIC, ACNU and VCR) and natural interferon-beta combination therapy in malignant melanoma.
Nagatani T; Ichiyama S; Onuma R; Miyazawa M; Matsuzaki T; Miyagawa K; Baba N; Uchiyama M; Nakajima H
Acta Derm Venereol; 1995 Nov; 75(6):494. PubMed ID: 8651034
[No Abstract] [Full Text] [Related]
5. [New combination chemotherapy for malignant melanoma--PAV(peplomycin, ACNU, VCR) therapy].
Ikeda S; Tajima K; Miyasato H; Terakado T; Suzuki T; Miura T
Gan To Kagaku Ryoho; 1983 Oct; 10(10):2198-204. PubMed ID: 6194756
[TBL] [Abstract][Full Text] [Related]
6. [Chemotherapy of malignant melanoma].
Ishihara K
Gan To Kagaku Ryoho; 1995 Jan; 22(1):23-7. PubMed ID: 7529980
[TBL] [Abstract][Full Text] [Related]
7. [Chemotherapy of malignant melanoma].
Ishihara K; Yamazaki N; Asano K
Gan To Kagaku Ryoho; 1993 Aug; 20(10):1287-92. PubMed ID: 7688498
[TBL] [Abstract][Full Text] [Related]
8. [Correlation between functional capability and phenotypic characteristics of peripheral blood lymphocytes in patients with malignant melanoma].
Konjević G; Jović V; Radomirović V; Spuzić I
Glas Srp Akad Nauka Med; 2002; (47):121-36. PubMed ID: 16078447
[TBL] [Abstract][Full Text] [Related]
9. Postoperative DAV-IFN-β therapy does not improve survival rates of stage II and stage III melanoma patients significantly.
Matsumoto T; Yokota K; Sawada M; Sakakibara A; Shibata S; Yasue S; Tomita Y; Yatsuya H; Akiyama M
J Eur Acad Dermatol Venereol; 2013 Dec; 27(12):1514-20. PubMed ID: 23198869
[TBL] [Abstract][Full Text] [Related]
10. [Case of metastatic malignant melanoma responded to combination chemotherapy with DTIC].
Tamura T; Miyamoto H; Harada M; Makinoya T; Yamamoto M; Miyoshi Y; Komi N
Gan To Kagaku Ryoho; 1984 Feb; 11(2):327-32. PubMed ID: 6582806
[TBL] [Abstract][Full Text] [Related]
11. Local administration of PF-3512676 CpG-B instigates tumor-specific CD8+ T-cell reactivity in melanoma patients.
Molenkamp BG; Sluijter BJ; van Leeuwen PA; Santegoets SJ; Meijer S; Wijnands PG; Haanen JB; van den Eertwegh AJ; Scheper RJ; de Gruijl TD
Clin Cancer Res; 2008 Jul; 14(14):4532-42. PubMed ID: 18628468
[TBL] [Abstract][Full Text] [Related]
12. Therapy-related myelodysplastic syndrome developed by dacarbazine, nimustine hydrochloride and vincristine sulfate (DAV) therapy for patient with malignant melanoma.
Nitta Y; Ikeya T; Sakakibara A; Tomita Y
J Dermatol; 2011 Feb; 38(2):164-8. PubMed ID: 21269313
[TBL] [Abstract][Full Text] [Related]
13. [Control of multiple skin and lung metastasis of malignant melanoma by combined DAV and OK-432 chemoimmunotherapy in association with large-scale administration of indomethacin].
Maeda K; Miura S; Kawamura M; Jimbow K
Gan To Kagaku Ryoho; 1984 Nov; 11(11):2434-7. PubMed ID: 6497401
[TBL] [Abstract][Full Text] [Related]
14. Perilesional treatment of metastatic melanoma with interferon-beta.
Fujimura T; Okuyama R; Ohtani T; Ito Y; Haga T; Hashimoto A; Aiba S
Clin Exp Dermatol; 2009 Oct; 34(7):793-9. PubMed ID: 19438554
[TBL] [Abstract][Full Text] [Related]
15. [Therapeutic response of interferon-beta in malignant melanoma].
Ishihara K
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 1):1010-6. PubMed ID: 2421645
[TBL] [Abstract][Full Text] [Related]
16. [A case of malignant melanoma responded to chemotherapy including DTIC and local injection of OK-432].
Tsuji H; Sawada S; Okano R; Shimazaki C; Nakanishi S; Haruyama H; Isemura T; Nakagawa M; Ijichi H; Ueda K
Gan To Kagaku Ryoho; 1982 Oct; 9(10):1851-5. PubMed ID: 6964031
[TBL] [Abstract][Full Text] [Related]
17. The expression of cytotoxic mediators is altered in mononuclear cells of patients with melanoma and increased by interferon-alpha treatment.
Guillot B; Portalès P; Thanh AD; Merlet S; Dereure O; Clot J; Corbeau P
Br J Dermatol; 2005 Apr; 152(4):690-6. PubMed ID: 15840100
[TBL] [Abstract][Full Text] [Related]
18. Two cases of malignant melanoma of the toe developed skin ulcers following local injection of natural beta-interferon.
Kurashige Y; Irisawa R; Abe N; Saito M; Tsuboi R
J Dermatol; 2012 Dec; 39(12):1037-8. PubMed ID: 22758215
[No Abstract] [Full Text] [Related]
19. [Long-term results of adjuvant chemotherapy after therapeutic lymph node dissection in patients with cutaneous malignant melanoma].
Kretschmer L; Helmbold P; Emmert S; Marsch WC
Hautarzt; 2002 Aug; 53(8):536-41. PubMed ID: 12221468
[TBL] [Abstract][Full Text] [Related]
20. Partial review of immunotherapeutic pharmacology in stem cell transplantation.
Bierman PJ; Abe F; Buyukberber S; Ino K; Talmadge JE
In Vivo; 2000; 14(1):221-36. PubMed ID: 10757081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
